Monopar Therapeutics Inc. (MNPR)
NASDAQ: MNPRHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
MNPR stock chart
Technical analysisKey statistics
All statistics- Market cap
- $467.60M
- EPS (TTM)
- -$2.44
- Dividend yield
- None
- 52-week range
- 50.07 – 124.82
- Day range
- 67.36 – 69.86
- Volume / Avg
- 132.61K / 151.83K
- Beta
- —
- Shares outstanding
- 6.78M
52-week range
MNPR stock today
Monopar Therapeutics (MNPR) closed at $69.00 on Nov 20, down 1.84% (-$1.29), versus the S&P 500's 3.70% decline. Shares are 44.7% below their 52-week high of $124.82, set on Aug 6, 2026 and 37.8% above the 52-week low of $50.07, in the middle of the past year's range. MNPR is up 5.7% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has lost 24.6%.
Monopar Therapeutics has posted a net loss over the last twelve months (EPS of -$2.44), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Monopar Therapeutics
Company profileMonopar Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. The company develops ALXN1840, a late-stage, investigational once-daily and oral medicine; MNPR-101, a proprietary humanized monoclonal antibody that is conjugated with different radioisotopes for the treatment of advanced solid tumors expressing urokinase plasminogen activator receptor; and MNPR-101-Zr, which is in phase 1 imaging and dosimetry clinical trial, a radiopharmaceutical imaging agent comprised of MNPR-101 conjugated to zirconium-89. It develops MNPR-101-Lu, a Phase1a stage radiotherapeutic comprised of MNPR-101 conjugated to actinium-225.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Chandler D. Robinson M.B.A., M.D., M.Sc.
- Headquarters
- Wilmette, IL
- Employees
- 22
- IPO year
- 2019
- Website
- monopartx.com
Financial highlights
Full financialsIn fiscal 2025, Monopar Therapeutics generated $0 in revenue, up 0.0% from fiscal 2024. Monopar Therapeutics reported a net loss of $13.7 million, compared with a loss of $15.6 million a year earlier.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $0 | $0 | — | — | — |
| Growth | — | — | — | — | — |
| Net income | $-13.72M | $-15.59M | $-8.40M | $-10.52M | $-9.10M |
| EPS (diluted) | — | — | — | — | $-0.73 |
Analyst forecast
ForecastConsensus (12 analysts)
strong_buy
Avg. price target
$130.17+88.65%
- Strong buy 4
- Buy 8
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 12, 2026
- EPS actual vs est.
- $-0.72 vs $-0.86
- Surprise
- +16.28%
MNPR news
All MNPR news- Monopar Therapeutics Inc. Reports Third Quarter 2026 Financial Results and Progresses ALXN1840 NDA SubmissionNasdaq
- Monopar Therapeutics Reports Third Quarter 2026 Financial Results and Provides Business UpdatesGlobeNewswire
- Monopar Presents Data Highlighting Residual Disease Burden in Treatment-Experienced Wilson Disease Patients and Long-Term Molybdenum Safety Data for ALXN1840 at AASLD – The Liver Meeting® 2026GlobeNewswire
Monopar Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| EVOEvotec SE ADR | 1.32 | -8.97% | $469.11M | vs MNPR |
| RZLTRezolute Inc. | 3.92 | -6.67% | $465.58M | vs MNPR |
| HELPHelus Pharma Inc. | 6.11 | -9.88% | $487.68M | vs MNPR |
| BLSMBlossomHill Therapeutics Inc. | 14.51 | +0.69% | $461.20M | vs MNPR |
| GYREGyre Therapeutics Inc. | 4.21 | -6.86% | $460.79M | vs MNPR |
| NGNENeurogene Inc. | 22.15 | -3.40% | $458.53M | vs MNPR |
| ASMBAssembly Biosciences Inc. | 22.19 | -1.38% | $454.39M | vs MNPR |
| STTKShattuck Labs Inc. | 4.46 | -1.98% | $454.22M | vs MNPR |
Indexes, lists and sector
Monopar Therapeutics stock FAQ
What is Monopar Therapeutics's stock price today?
MNPR last traded at $69.00 as of Nov 20, 4:00 PM EST, down 1.84% on the day. Prices are delayed at least 15 minutes.
Does Monopar Therapeutics pay a dividend?
No. Monopar Therapeutics does not currently pay a regular cash dividend.
Who is Monopar Therapeutics's CEO?
Dr. Chandler D. Robinson M.B.A., M.D., M.Sc. is the chief executive officer of Monopar Therapeutics Inc., which has about 22 employees.
Has MNPR ever split its stock?
Yes. The most recent MNPR stock split was a 1-for-5 split on Aug 13, 2024.
What is the MNPR 52-week high?
The 52-week high for MNPR is $124.82 and the 52-week low is $50.07. The stock is currently 44.7% below its high.